Serina Therapeutics Inc (SER) - Total Assets
Based on the latest financial reports, Serina Therapeutics Inc (SER) holds total assets worth $12.41 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Serina Therapeutics Inc for net asset value and shareholders' equity analysis.
Serina Therapeutics Inc - Total Assets Trend (2016–2024)
This chart illustrates how Serina Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Serina Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Serina Therapeutics Inc's total assets of $12.41 Million consist of 84.4% current assets and 15.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $3.67 Million | 54.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $1.05 Million | 15.6% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Serina Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Serina Therapeutics Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Serina Therapeutics Inc's current assets represent 84.4% of total assets in 2024, an increase from 21.4% in 2016.
- Cash Position: Cash and equivalents constituted 54.6% of total assets in 2024, up from 8.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is cash and equivalents at 54.6% of total assets.
Serina Therapeutics Inc Competitors by Total Assets
Key competitors of Serina Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
Serina Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.31 | 0.40 | 0.43 |
| Quick Ratio | 1.31 | 0.40 | 0.43 |
| Cash Ratio | 0.98 | 0.24 | 0.00 |
| Working Capital | $2.71 Million | $-8.09 Million | $-3.07 Million |
Serina Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Serina Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 29.88 |
| Latest Market Cap to Assets Ratio | 2.65 |
| Asset Growth Rate (YoY) | -25.0% |
| Total Assets | $6.72 Million |
| Market Capitalization | $17.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Serina Therapeutics Inc's assets at a significant premium (2.65x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Serina Therapeutics Inc's assets decreased by 25.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Serina Therapeutics Inc (2016–2024)
The table below shows the annual total assets of Serina Therapeutics Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.72 Million | -25.02% |
| 2023-12-31 | $8.97 Million | +176.70% |
| 2022-12-31 | $3.24 Million | +2.76% |
| 2021-12-31 | $3.15 Million | -19.64% |
| 2020-12-31 | $3.92 Million | -47.26% |
| 2019-12-31 | $7.44 Million | -30.26% |
| 2018-12-31 | $10.67 Million | +10.80% |
| 2017-12-31 | $9.63 Million | +198.82% |
| 2016-12-31 | $3.22 Million | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more